Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,592 shares, a growth of 92.7% from the June 15th total of 1,864 shares. Based on an average daily volume of 7,451 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the shares of the company are sold short.

Invesco Biotechnology & Genome ETF Price Performance

PBE stock opened at $91.03 on Friday. The stock has a market cap of $285.83 million, a price-to-earnings ratio of 20.44 and a beta of 0.70. The company has a fifty day moving average price of $85.83 and a two-hundred day moving average price of $82.54. Invesco Biotechnology & Genome ETF has a one year low of $63.92 and a one year high of $94.06.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

Several hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. increased its stake in shares of Invesco Biotechnology & Genome ETF by 9,169.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock worth $28,175,000 after purchasing an additional 339,271 shares during the period. LPL Financial LLC lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 5.0% during the fourth quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock worth $7,994,000 after buying an additional 4,617 shares in the last quarter. United Capital Financial Advisors LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $5,946,000. Royal Bank of Canada grew its stake in shares of Invesco Biotechnology & Genome ETF by 22.3% in the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock valued at $4,783,000 after acquiring an additional 13,767 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Invesco Biotechnology & Genome ETF by 2.5% during the third quarter. Bank of America Corp DE now owns 59,918 shares of the company’s stock worth $4,186,000 after acquiring an additional 1,453 shares during the period.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.